Literature DB >> 16223974

Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.

Lorraine Lipfert1, John E Fisher, Nan Wei, Angela Scafonas, Qin Su, Joel Yudkovitz, Fang Chen, Sudha Warrier, Elizabeth T Birzin, Seongkon Kim, Helen Y Chen, Qiang Tan, Azriel Schmidt, Frank Dininno, Susan P Rohrer, Milton L Hammond, Gideon A Rodan, Leonard P Freedman, Alfred A Reszka.   

Abstract

Estrogen receptor alpha (ERalpha) serine 118 (Ser118) phosphorylation modulates activation function-1 (AF1) function. Correct positioning of helix 12 promotes agonist-dependent recruitment of cyclin-dependent kinase-7 to catalyze this event. In this study we show robust cyclin-dependent kinase-7-independent, AF2 antagonist-induced Ser118 phosphorylation. Estradiol (E2) and ICI-182,780 (ICI-780) induce Ser118 phosphorylation of wild-type ERalpha and either of two helix 12 mutants, suggesting AF2-independent action, probably via shedding of 90-kDa heat shock protein. With E2 treatment, the predominantly nuclear, phosphorylated ERalpha in COS-1 cells is detergent soluble. Although levels of ICI-780-induced phosphorylation are profound, Ser118-phosphorylated ERalpha is aggregated over the nucleus or in the cytoplasm, fractionating with the cell debris and making detection in cleared lysates improbable. Selective ER modulators (SERMs) elicit a mixed response with phosphorylated ERalpha in both detergent-soluble and -insoluble compartments. Apparent ligand-induced loss of ERalpha protein from cleared lysates is thus due to ligand-induced redistribution into the pellet, not degradation. The COS-1 response to ICI-780 can be mimicked in MCF-7 cells treated with a proteasome inhibitor to block authentic ligand-induced degradation. With SERMs and antagonists, the magnitude of Ser118-phosphorylated receptor redistribution into the insoluble fraction of COS-1 cells correlates with the magnitude of authentic ERalpha degradation in MCF-7 cells. A strong inverse correlation with ligand-induced uterotropism in vivo (P < 0.0001) and direct correlation with AF2-independent transrepression of the matrix metalloprotease-1 promoter in endometrial cells in vitro are seen. These data suggest that ligand-induced Ser118 phosphorylation of ERalpha can be AF2 independent. Furthermore, they identify translocation of Ser118-phosphorylated ERalpha out of the nucleus, leading to cytoplasmic aggregation, as an antagonist pathway that may precede receptor degradation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223974     DOI: 10.1210/me.2005-0190

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  5 in total

1.  The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.

Authors:  Suzanne E Wardell; Jeffrey R Marks; Donald P McDonnell
Journal:  Biochem Pharmacol       Date:  2011-04-09       Impact factor: 5.858

Review 2.  CAR and PXR: the xenobiotic-sensing receptors.

Authors:  Yoav E Timsit; Masahiko Negishi
Journal:  Steroids       Date:  2006-12-20       Impact factor: 2.668

3.  Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity.

Authors:  Ross S Thomas; Naveed Sarwar; Fladia Phoenix; R Charles Coombes; Simak Ali
Journal:  J Mol Endocrinol       Date:  2008-04       Impact factor: 5.098

4.  Activation of estrogen receptor-alpha by E2 or EGF induces temporally distinct patterns of large-scale chromatin modification and mRNA transcription.

Authors:  Valeria Berno; Larbi Amazit; Cruz Hinojos; Jeannie Zhong; Maureen G Mancini; Zelton Dave Sharp; Michael A Mancini
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

5.  Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays.

Authors:  Debabrata Mahapatra; Jill A Franzosa; Kyle Roell; Melaine Agnes Kuenemann; Keith A Houck; David M Reif; Denis Fourches; Seth W Kullman
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.